Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7510726 | ZYLA | Methods and compositions for deterring abuse of opioid containing dosage forms |
Nov, 2023
(5 months from now) | |
US7981439 | ZYLA | Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof |
Nov, 2023
(5 months from now) | |
US8409616 | ZYLA | Extended release opioid abuse deterrent compositions and methods of making same |
Nov, 2023
(5 months from now) | |
US8637540 | ZYLA | Compositions for deterring abuse of opioid containing dosage forms |
Nov, 2023
(5 months from now) | |
US9492443 | ZYLA | Abuse deterrent compositions and methods of making same |
May, 2024
(11 months from now) | |
US7201920 | ZYLA | Methods and compositions for deterring abuse of opioid containing dosage forms |
Mar, 2025
(1 year, 9 months from now) |
Market Authorisation Date: 17 June, 2011
Treatment: NA
Dosage: TABLET;ORAL
13
United States
5
Australia
3
European Union
2
Israel
1
Spain
1
Canada
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10696684 | PURDUE PHARMA LP | Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(1 year, 9 months from now) | |
US10407434 | PURDUE PHARMA LP | Process for preparing oxycodone compositions |
Mar, 2025
(1 year, 9 months from now) | |
US9522919 | PURDUE PHARMA LP | Oxycodone compositions |
Mar, 2025
(1 year, 9 months from now) | |
US9073933 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(1 year, 9 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9675610 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(14 days from now) | |
US10369109 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(14 days from now) | |
US8309060 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(5 months from now) | |
US10130591 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(5 months from now) | |
US10675278 | PURDUE PHARMA LP | Crush resistant delayed-release dosage forms |
Nov, 2023
(5 months from now) | |
US11304909 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
US8808741 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
US9492393 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
US9492391 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
US9492389 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
US9492392 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
US9770416 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
US9775808 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
US8894988 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
US9763933 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
US11304908 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(4 years from now) | |
US8894987 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Mar, 2030
(6 years from now) |
Market Authorisation Date: 05 April, 2010
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require ...
Dosage: TABLET, EXTENDED RELEASE;ORAL
180
United States
35
European Union
26
Spain
26
Slovenia
25
Denmark
25
Poland
25
Portugal
24
Korea, Republic of
24
Cyprus
23
Japan
22
Hong Kong
22
Croatia
20
China
19
Germany
17
Israel
16
RS
13
Argentina
12
Austria
12
Peru
12
Australia
11
ME
9
Canada
9
New Zealand
7
Brazil
6
Malaysia
6
Hungary
5
Chile
5
Taiwan
5
Mexico
5
South Africa
4
Russia
4
EA
4
Norway
4
Costa Rica
3
Ukraine
3
Singapore
3
Ecuador
3
Lithuania
2
Dominican Republic
2
Morocco
2
Guatemala
2
Jordan
2
Tunisia
1
IB
1
India
1
AP
1
Georgia
1
Finland
1
Colombia
1
Saudi Arabia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7955619 | PROTEGA PHARMS | Abuse resistant drugs, method of use and method of making |
Aug, 2028
(5 years from now) | |
US10314788 | PROTEGA PHARMS | Pharmaceutical compositions configured to deter dosage form splitting |
Aug, 2028
(5 years from now) |
Market Authorisation Date: 20 April, 2017
Treatment: NA
Dosage: TABLET;ORAL
28
United States
5
Australia
3
Canada
2
China
2
Japan
2
European Union
1
Poland
1
Spain
1
Brazil
1
Mexico
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic